hurt non-op loss core busi see good momentum
result ep preliminari un-
audit result due higher non-op loss ep
yoy divest gain op yoy
higher sale contribut oncolog anti-infect bod
propos dividend approv impli yield
busi continu grow tti expect oncolog ex
grow yoy anti-infect see boost taiwan
vaccin bid doxil remain stabl expect
sales/op grow yoy ep increas yoy
greater revenu scale less non-op loss
caus new project delay colimycin
cfda review approv process could delay six
month given outbreak octreotid final
negoti partner expect compet
lower ep push-out colimycin
approval/onivyd mileston maintain outperform rate
lower tp roll-ov average
price-to-earnings believ improv op support stock
result
tti post result market close march ep
preliminari un-audit result mainli
due greater loss affili cy includ
mn revalu loss recal weight manag
medicin belviq
sale taiwan safeti concern
follow drug manufactur eisai decis us due possibl
increas risk cancer ep yoy
divest gain sales/op yoy higher
contribut oncolog anti-infect tti bod propos
cash dividend approv impli yield
figur tti result write-off
number share mn
chg prev ep
estimate pot chg tp
expect tti ep grow
yoy greater revenu scale less non-op loss
tti state colimycin tam bn cfda review
year believ outbreak delay
approv process anoth six month believ colimycin
could main driver anti-infect busi china post
approv octreotid tti state final negoti
partner expect complet final agreement
launch also expect lipo-ab receiv fda approv
product launch term product current
sourc api europ china
india month inventori hand
lower ep delay approv colimycin
china push-out pharmaengin onivyd mileston incom
maintain outperform lower tp
roll-ov averag price-to-earnings past averag
believ improv core busi potenti catalyst
drug approv support share price
compani data bloomberg profession servic
busi continu grow
tti expect oncolog exclud sale grow
yoy new product lonsurf painkyl prolifer
enter taiwan nih system anti-infect busi
benefit new round influenza vaccin bid taiwan
year total sale increment mn also
expect doxil remain stabl line view
estim tti sale grow yoy driven
oncolog yoy includ anti-infect yoy
gm dilut taiwan influenza vaccin
forecast gm/opm
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
jerri su harvi chou certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori johnson johnson jnj
signifi initi assumpt coverag
price rate histori tti biopharm
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
charl martineau pm univers toronto overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
